J Dig Cancer Res.
2024 Dec;12(3):229-233. 10.52927/jdcr.2024.12.3.229.
Emerging Prospects for Combining Immune Checkpoint Inhibitors with Loco-regional Therapy in Hepatocellular Carcinoma
- Affiliations
-
- 1Department of Internal Medicine, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea
- 2Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea
- 3Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea
- KMID: 2563748
- DOI: http://doi.org/10.52927/jdcr.2024.12.3.229
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Advances in immune checkpoint inhibitors for hepatocellular carcinoma
- Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Gastrointestinal cancer treatment with immune checkpoint inhibitors
- Treatment of advanced urogenital cancers with immune checkpoint inhibitors
